NORGINE COMPLETES AGREEMENT WITH ASPEN FOR ITS SOUTHERN AFRICAN OPERATIONS AND PRODUCT RIGHTS

London. 30 September 2015, 14:00 BST. Norgine B.V. today announced that it has completed its agreement with Pharmacare Limited, a wholly owned subsidiary of Aspen Pharmacare Holdings (collectively “Aspen”) for the divestment of its Southern African operations and product rights.

The approval of this transaction by the South African Competition Authorities was obtained on 25 August 2015.

Peter Stein, Norgine CEO said: “This transaction reinforces Norgine’s European strategic focus. We will continue to leverage our European business and to seek collaboration opportunities to acquire further specialist products for sale through Norgine’s infrastructure.”

Notes to Editors:

About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine’s total revenue was €296 million and the company employs over 1,000 people.

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

Media Contacts:

Isabelle Jouin, T: +44 (0)1895 453643

Charlotte Andrews, T: +44 (0)1895 453607

Follow us @norgine